|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.140 USD | -12.29% |
|
-10.08% | -52.02% |
| 07-08 | Seres Therapeutics Announces Early Clinical Data Showing Potential For SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis | CI |
| 07-08 | Seres Therapeutics, Inc. - Special Call |
| Market Cap | 69.14M 60.65M 55.99M 51.74M 98.07M 6.62B 100M 673M 262M 3.24B 260M 254M 11.25B | P/E 2026 * |
-0.95x | P/E 2027 * | -1.09x |
|---|---|---|---|---|---|
| Enterprise Value | 69.14M 60.65M 55.99M 51.74M 98.07M 6.62B 100M 673M 262M 3.24B 260M 254M 11.25B | EV / Sales 2026 * |
5.38x | EV / Sales 2027 * | 193x |
| Free-Float |
88.22% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Seres Therapeutics, Inc.
| 1 day | -12.29% | ||
| 1 week | -10.08% | ||
| Current month | -9.51% | ||
| 1 month | +13.69% | ||
| 3 months | -18.49% | ||
| 6 months | -53.79% | ||
| Current year | -52.02% |
| 1 week | 6.99 |  | 8.25 |
| 1 month | 5.31 | | 8.25 |
| Current year | 5.31 | | 16.42 |
| 1 year | 5.31 | | 29.98 |
| 3 years | 5.31 | | 105.8 |
| 5 years | 5.31 | | 437.8 |
| 10 years | 5.31 | | 770 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Kender
CEO | Chief Executive Officer | 70 | 01/03/2026 |
Ann Thorell
CEO | Chief Executive Officer | 58 | 31/07/2025 |
Matthew Henn
PSD | President | 51 | 01/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard Kender
CHM | Chairman | 70 | 01/03/2026 |
Eric Shaff
BRD | Director/Board Member | 50 | 14/01/2019 |
Dennis Ausiello
BRD | Director/Board Member | 80 | 31/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-30 | Free | Director | 7,508 | 0.0775% | ||
| 06-30 | Free | Director | 7,508 | 0.0775% | ||
| 06-30 | Free | Director | 7,508 | 0.0775% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -12.29% | -10.08% | -38.45% | -92.50% | 69.14M | |
| -1.03% | -3.97% | +70.41% | +125.37% | 56.71B | |
| -2.45% | -7.83% | +63.92% | +83.15% | 51.3B | |
| +3.27% | +8.91% | +21.21% | +486.76% | 25.26B | |
| -0.81% | -0.42% | -16.24% | -12.47% | 23.65B | |
| +3.98% | +3.29% | +43.01% | -2.53% | 18.69B | |
| -0.17% | +0.80% | +37.73% | -26.07% | 17.71B | |
| +2.34% | +12.50% | +224.02% | +380.99% | 17.7B | |
| -1.34% | +1.15% | +35.22% | - | 14.26B | |
| -1.70% | +3.98% | +28.96% | +190.57% | 14.1B | |
| Average | -1.02% | +3.93% | +46.98% | +125.92% | 23.95B | |
| Weighted average by Cap. | -0.20% | +2.20% | +57.50% | +143.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 12.86M 11.28M 10.41M 9.62M 18.24M 1.23B 18.6M 125M 48.63M 602M 48.29M 47.23M 2.09B | 358K 314K 290K 268K 508K 34.28M 518K 3.49M 1.35M 16.77M 1.34M 1.31M 58.23M |
| Net income | -70.97M -62.25M -57.47M -53.1M -101M -6.8B -103M -691M -268M -3.33B -267M -261M -11.54B | -99.82M -87.56M -80.83M -74.7M -142M -9.56B -144M -972M -378M -4.68B -375M -367M -16.24B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/07/26 | US$7.140 | -12.29% | 258,095 |
| 07/07/26 | US$8.140 | +5.58% | 98,987 |
| 06/07/26 | US$7.710 | -0.39% | 31,504 |
| 02/07/26 | US$7.740 | -2.52% | 130,834 |
| 01/07/26 | US$7.940 | +0.63% | 150,876 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MCRB Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
